Concord Biotech Limited Stock

Equities

CONCORDBIO

INE338H01029

Pharmaceuticals

Delayed NSE India S.E. 02:35:53 2024-06-13 am EDT 5-day change 1st Jan Change
1,445 INR +0.94% Intraday chart for Concord Biotech Limited -1.54% -1.87%
Sales 2024 10.17B 122M Sales 2025 * 12.45B 149M Capitalization 150B 1.79B
Net income 2024 3.08B 36.88M Net income 2025 * 3.91B 46.84M EV / Sales 2024 15.6 x
Net cash position 2024 * 630M 7.54M Net cash position 2025 * 2.68B 32.14M EV / Sales 2025 * 11.8 x
P/E ratio 2024
51.6 x
P/E ratio 2025 *
38.3 x
Employees 1,180
Yield 2024 *
0.44%
Yield 2025 *
0.69%
Free-Float 24.61%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.89%
1 week-1.54%
Current month-1.31%
1 month-4.17%
3 months+5.19%
6 months+9.23%
Current year-1.87%
More quotes
1 week
1 426.05
Extreme 1426.05
1 475.00
1 month
1 327.05
Extreme 1327.05
1 529.85
Current year
1 327.05
Extreme 1327.05
1 725.00
1 year
900.05
Extreme 900.05
1 725.00
3 years
900.05
Extreme 900.05
1 725.00
5 years
900.05
Extreme 900.05
1 725.00
10 years
900.05
Extreme 900.05
1 725.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 42 09-12-03
Chief Executive Officer 71 00-05-09
Director of Finance/CFO 58 22-03-13
Members of the board TitleAgeSince
Director/Board Member 64 22-05-23
Director/Board Member 79 17-01-30
Director/Board Member 56 17-01-30
More insiders
Date Price Change Volume
24-06-13 1,445 +0.94% 20 424
24-06-12 1,432 -1.20% 49,844
24-06-11 1,449 +0.08% 51,485
24-06-10 1,448 -0.39% 135,781
24-06-07 1,454 -0.92% 48,040

Delayed Quote NSE India S.E., June 13, 2024 at 02:35 am EDT

More quotes
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. It manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. It also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The Company provides products in the critical care, immunology, nephrology, and transplant medicine segments.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,432 INR
Average target price
1,592 INR
Spread / Average Target
+11.21%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. CONCORDBIO Stock